EpiCast Report: Sepsis and Septic Shock – Epidemiology Forecast to 2026

2017-08-01
Price :
Published : Aug-2017
No. of Pages : 61

EpiCast Report: Sepsis and Septic Shock – Epidemiology Forecast to 2026

Summary

Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection damages its own tissues and organs. Sepsis can lead to multiple organ failure and death, especially if it is not recognized early and treated promptly (Elfeky et al., 2017; Mayo Clinic, 2016). Anyone can develop sepsis; however, the condition is more common among children less than one year of age, older adults, and those with weakened immune systems (Elfeky et al., 2017; Mayo Clinic, 2016).

In men and women, among the 7MM in 2016, the US had the highest age-standardized diagnosed incidence of sepsis and Japan had the lowest. In the 5EU (France, Germany, Italy, Spain, UK), the age-standardized diagnosed incidence of sepsis in men ranged between 94.91 cases per 100,000 population in France and 174.05 cases per 100,000 population in the UK in 2016. The age-standardized diagnosed incidence of sepsis in women in the 5EU ranged between 36.76 cases per 100,000 population in France and 128.05 cases per 100,000 populations in the UK in 2016. Due to data scarcity, the crude diagnosed incidence of sepsis for Italy is considered to be same as that of Spain and therefore the calculated age-standardized diagnosed incidence rates are also similar in these markets.

Among the 7MM, in men and women in 2016, the US had the highest age-standardized diagnosed incidence of septic shock and Japan had the lowest. In the 5EU, the age-standardized diagnosed incidence of sepsis in men ranged between 29.55 cases per 100,000 population in Germany and 52.57 cases per 100,000 population in the UK in 2016. Similarly, the age-standardized diagnosed incidence of septic shock in women in the 5EU ranged between 11.56 cases per 100,000 population in France and 38.86 cases per 100,000 population in the UK in 2016. Due to data scarcity, the crude diagnosed incidence of septic shock for Italy is considered to be same as that of Spain and therefore, the calculated age-standardized diagnosed incidence rates are also similar in these markets.

The report “EpiCast Report: Sepsis and Septic Shock – Epidemiology Forecast to 2026″, provides an overview of the risk factors, comorbidities, and the global and historical trends for sepsis and septic shock in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of sepsis and septic shock, segmented by sex and by age (for all ages).

In depth, this report provides the following –
- The sepsis and septic shock epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Scope

- The Sepsis and Septic Shock EpiCast Report provides an overview of the risk factors and global trends of sepsis and septic shock in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of sepsis and septic shock, segmented by age (for all ages) and sex. The sepsis and septic shock diagnosed incident cases are further segmented by causative agent and organ dysfunction. Additionally, GlobalData epidemiologists provide a forecast for the in-hospital mortality cases of sepsis and septic shock, segmented by age for both sexes.
- The sepsis and septic shock epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Sepsis and Septic Shock EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global sepsis and septic shock market.
- Quantify patient populations in the global sepsis and septic shock market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for sepsis and septic shock therapeutics in each of the markets covered.
- Understand the causative agent, organ dysfunction, and mortality of sepsis and septic shock.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

Hemostasis Global Clinical Trials Review, H2, 2017

Hemostasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemostasis Global Clinical Trials Review, H2, 2017" provides an overview of Hemostasis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemostasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Hemochromatosis Global Clinical Trials Review, H2, 2017

Hemochromatosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemochromatosis Global Clinical Trials Review, H2, 2017" provides an overview of Hemochromatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemochromatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Encephalopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Encephalopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma e......
$2500

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hepatorenal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatorenal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Hemoglobinopathies Global Clinical Trials Review, H2, 2017

Hemoglobinopathies Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemoglobinopathies Global Clinical Trials Review, H2, 2017" provides an overview of Hemoglobinopathies clinical trials scenario. This report provides top line data relating to the clinical trials on Hemoglobinopathies. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Hepatic Injury Global Clinical Trials Review, H2, 2017

Hepatic Injury Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Injury Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.......
$2500

Hemoglobinuria Global Clinical Trials Review, H2, 2017

Hemoglobinuria Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemoglobinuria Global Clinical Trials Review, H2, 2017" provides an overview of Hemoglobinuria clinical trials scenario. This report provides top line data relating to the clinical trials on Hemoglobinuria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500